Apomorphine-induced disruption of prepulse inhibition that can be normalised by systemic haloperidol is insensitive to clozapine pretreatment by Russig, H. et al.
Psychopharmacology (2004) 175:143–147
DOI 10.1007/s00213-004-1810-1
O R I G I NA L I NVE S T I GA T I ON
H. Russig · W. Spooren · S. Durkin · J. Feldon ·
B. K. Yee
Apomorphine-induced disruption of prepulse inhibition
that can be normalised by systemic haloperidol is insensitive
to clozapine pretreatment
Received: 7 August 2003 / Accepted: 13 October 2003 / Published online: 25 February 2004
 Springer-Verlag 2004
Abstract Rationale: Prepulse inhibition (PPI) of startle
refers to the phenomenon in which a weak prepulse
attenuates the startle response to a succeeding intense
stimulus. PPI can be disrupted by systemic apomorphine
in animals, and reduced PPI has been consistently
reported in schizophrenia patients. The ability of the
atypical antipsychotic clozapine to reverse apomorphine-
induced PPI deficit has been demonstrated in the rat, but
has not yet been tested in the mouse. The present study
was designed to fill this gap. Objective and results: We
investigated the efficacy of clozapine in reversing apo-
morphine-induced (2.0 or 2.5 mg/kg, SC) PPI deficit
in C57BL6 mice. Clozapine failed to restore PPI disrup-
tion in apomorphine-treated mice in two independent
laboratories across two dose ranges (1–3 mg/kg, IP, or 3–
30 mg/kg, PO), whereas the typical antipsychotic halo-
peridol (1 mg/kg,IP) completely normalised PPI perfor-
mance. Conclusions: Unlike the rat, apomorphine-in-
duced PPI disruption in mice might be instrumental in
distinguishing between typical and atypical antipsychotic
drugs. This also lends further support to the suggestion
that the neuropharmacology of PPI is not identical in the
two rodent species.
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Introduction
Prepulse inhibition (PPI) refers to the reduction in startle
reaction towards a startle-eliciting “pulse” stimulus when
it is shortly preceded by a sub-threshold “prepulse”
stimulus (Hoffman and Searle 1965). Dopamine agonist-
induced PPI disruption is often employed as an animal
model of sensorimotor gating deficits in schizophrenia, as
PPI is similarly impaired in schizophrenia patients (Braff
et al. 2001). More importantly, such drug-induced deficits
can be ameliorated by antipsychotic drugs in the rat (Braff
et al. 2001).
The pharmacology of PPI has been extensively studied
in the rat (see review by Geyer et al. 2001). Nevertheless,
parallel investigations in mice have only begun recently
with the availability of genetically modified mice, and
with it the opportunity to study the genetic basis of
sensorimotor gating. However, the possibility that the
molecular neuropharmacology of PPI might differ be-
tween the rat and the mouse has been raised (Geyer et al.
2002; Ralph-Williams et al. 2002, 2003). Confirmation of
the predictive validity of an animal model requires the
model to be sensitive to known clinically effective drugs.
This has been firmly established in the rat with both
typical and atypical neuroleptic drugs, but equivalent
confirmation is still lacking in the mouse. Hence, a clear
consensus has yet to be established in the mouse, in
particular, with respect to atypical neuroleptic drugs.
One strategy to evaluate potential antipsychotic prop-
erty is to assess a compound’s ability to enhance PPI in
the absence of any treatment-induced deficit (Depoortere
et al. 1997; Ouagazzal et al. 2001). A number of typical
and atypical neuroleptic compounds (including haloper-
idol, risperidone, and clozapine) have been shown to
enhance PPI in different mouse strains when administered
on their own (Curzon and Decker 1998; Olivier et al.
2001; Ouagazzal et al. 2001; Geyer et al. 2002). However,
unlike the typical antipsychotic drug haloperidol (Curzon
and Decker 1998; Furuya et al. 1999), the efficacy of
atypical antipsychotic drugs to reverse apomorphine-
induced PPI deficit has not been convincingly demon-
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strated in the mouse. The effectiveness of clozapine in
reversing apomorphine-induced PPI disruption has been
well established in the rat; however, equivalent demon-
stration in the mouse is still lacking.
The present study was designed to address this in
C57BL6/J mice. C57BL6/J mice exhibit robust PPI,
which can be disrupted by systemic apomorphine (Curzon
and Decker 1998; Varty et al. 2001). This mouse strain is
also widely used in murine behavioural testing, and is
increasingly popular amongst behavioral geneticists given
its superior performance across a wide spectrum of
behavioral assays in comparison to other strains, e.g.
those from the 129 family.
Two independent experiments were conducted in two
laboratories (Zurich and Basel). Each experiment exam-
ined three doses of clozapine given prior to apomorphine
administration in comparison to apomorphine or vehicle
treatment alone. Experiment 1 (in Zurich) also included
two doses of haloperidol: with one dose serving as
positive control (at 1 mg/kg, IP), and a lower dose as a
negative control (at 0.2 mg/kg, IP). These doses were
selected based on pilot studies performed in the Zurich
laboratory.
Materials and methods
Subjects. The subjects were male naive C57BL6/J mice, weighing
28–35 g. For experiment 1, they were obtained from the in-house
specific-pathogen-free (SPF) breeding facility in the Zurich labo-
ratory. For experiment 2, they were obtained from Iffa Credo
(France). The animals were caged in groups of three or four
littermates under a reversed light–dark cycle (lights on 2000–
0800 hours) in a temperature- (21€1C) and humidity- (55€5%)
controlled animal facility, with ad lib food and water. In the
allocation of subjects to treatment groups, mice derived from the
same litters were always allocated into different groups, so as to
minimize possible confounds due to litter effects (Zorrilla 1997).
Experiment 1 was carried out during the dark phase of the light–
dark cycle, and experiment 2 during the light phase. All procedures
involved were in agreement with Swiss regulations for animal
experimentation.
Apparatus. These consisted of a set of two (Zurich), or eight (Basel)
acoustic startle chambers (SR-LAB; San Diego Instruments, San
Diego, Calif., USA), each comprising a non-restrictive cylindrical
enclosure made of clear Plexiglas attached horizontally on a mobile
platform, which was in turn resting on a solid base inside a sound-
attenuated isolated cubicle. A high-frequency loudspeaker mounted
directly above the animal enclosure inside each cubicle produced
both a continuous background noise of 65 dBA and various acoustic
stimuli in the form of white noise. Vibrations of the Plexiglas
enclosure caused by the whole-body startle response of the animal
were transduced into analogue signals by a piezoelectric unit
attached to the platform. These signals were then digitized and
stored by a computer. A total of 130 readings were taken at 0.5-ms
intervals (i.e. spanning across 65 ms), starting at the onset of the
startle stimulus in pulse-alone and prepulse-plus-pulse trials, and at
the onset of the prepulse stimulus in prepulse-alone trials. The
average amplitude over the 65 ms was used to determine the
stimulus reactivity. The sensitivity of the stabilimeter was routinely
calibrated to ensure consistency between chambers and across
sessions.
Procedures. The two experiments were performed in two indepen-
dent laboratories (experiment 1: the Swiss Federal Institute of
Technology Zurich, and experiment 2: F. Hoffmann-La Roche
Basel) in order to have two independent sets of data. In the
demonstration of PPI of the acoustic startle reflex, subjects were
presented with a series of discrete trials comprising a mixture of
four types of trials. These included pulse-alone trials, prepulse-
plus-pulse trials, prepulse-alone trials, and trials in which no
discrete stimulus, other than the constant background noise, was
presented. A reduction of startle magnitude in prepulse-plus-pulse
trials relative to that in pulse-alone trials constitutes PPI. The pulse
stimulus employed was 120 dBA in intensity and 40 ms in duration.
Prepulses of various intensities were employed: 69, 73, 77, 81,
and 85 dBA in experiment 1 or 69, 73, 77, and 81 dBA in experiment
2, which corresponded to 4, 8, 12, 16, and additionally 20 dBA
(experiment 1 only) above background. The duration of prepulse
stimuli was 20 ms. The SOA (stimulus onset asynchrony) of the
prepulse and pulse stimuli on prepulse-plus-pulse trials was 100 ms.
A session began with the animals being placed into the
Plexiglas enclosure. They were acclimatised to the apparatus for
2 min before the first trial began. The first six trials consisted of
startle-alone trials only, and they served to habituate and stabilise
the animals’ startle response. Subsequently, there were 120 trials
comprising 12 blocks of trials each. Each block consisted of one
trial of each of the following trial types: startle-alone, prepulse-
plus-pulse trials of each of the 4–5 levels of prepulse, prepulse-
alone of each of the 4–5 levels of prepulse, and no stimulus (i.e.
background alone). The interval between successive trials was
variable, with a mean of 15 s (ranged 10–20 s). The test session
lasted for approximately 40 min in experiment 1, and 30 min in
experiment 2.
Drugs. All solutions were freshly prepared on the day of testing,
and were administered in a volume of 5 ml/kg. Apomorphine HCl
(APO, obtained from Sigma Chemicals, St Louis, USA) was
dissolved in sterile 1% ascorbic acid (VitC, pH 3.2) to achieve the
desired concentration (2.0 and 2.5 mg/kg for experiments 1 and 2,
respectively; both at pH 3.1). Haloperidol (HAL, obtained from
Janssen-Cilag, Baar, Switzerland) was prepared from 5-mg am-
poules, in which the drug was present in 1 ml of solvent containing
6 mg lactic acid. This was diluted with sterile 0.9% NaCl solution
to obtain the required concentration of either 0.2 or 1.0 mg/kg (final
pH of 5.5). Clozapine (CLZ, obtained from F. Hoffmann-La Roche,
Switzerland) was prepared differently for the two experiments,
depending on the chosen routes of administration. In experiment 1,
it was first dissolved in 0.1 N HCl in 0.9% saline solution and then
neutralised to pH 5.5 with Na2CO3 to obtain the three required
doses: 1.0, 2.0, and 3.0 mg/kg. In experiment 2, clozapine was
micro-suspended in a mixture of Tween-80 (0.3%)–saline (0.9%) to
obtain the three required doses: 3.0, 15.0, and 30.0 mg/kg.
The first injection (HAL, CLZ, or the corresponding vehicle
solution) was made 60 min before testing, either via the intraperi-
toneal route in experiment 1 or per os (PO) in experiment 2. In
experiment 1, half of the animals receiving vehicle treatment as
their first injection were given 0.9% saline/lactic acid, pH 5.5
(vehicle for haloperidol), and the other half 0.1 N HCl/0.9% saline,
pH 5.5 (vehicle for clozapine). In experiment 2, the animals
receiving vehicle as their first treatment were all given the Tween-
80 (0.3%)–saline (0.9%) mixture.
The second injection was either APO or VitC, and was
administered 15 min before testing via the subcutaneous (SC)
route in both experiments.
Data analysis. The test trials following the first six acclimatisation
trials of startle-alone trials were sub-divided into different trial
types and the average values obtained for each individual animal.
Percentage prepulse inhibition (%PPI) at each level of prepulse
intensity was then calculated with the formula: [(pulse-alone 
prepulse-plus-pulse)/pulse-alone100%].
Startle reactivity across the 12 pulse-alone trials (excluding the
first six startle-alone trials), and percent PPI were separately
analysed using two-way ANOVAs with the between-subjects
treatment factor, and the appropriate repeated measures (prepulse
intensities or blocks of two trials). Significant effects were further
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examined by post hoc pair-wise comparisons using the Student-
Newman–Keuls procedure.
The number of subjects in each of the seven groups in
experiment 1 were VEH/VitC, n=9; VEH/APO, n=9; CLZ1/APO,
n=10; CLZ2/APO, n=9; CLZ3/APO, n=10; HAL0.2/APO, n=10;
HAL1.0/APO, n=10. The number of subjects in each of the five
groups in experiment 2 were VEH/VitC, n=9; VEH/APO, n=9;
CLZ3/APO, n=9; CLZ15/APO, n=6; CLZ30/APO, n=6.
Results
Experiment 1 (Zurich)
The presence of a prepulse reduced the startle response to
the succeeding startle stimulus, and constituted the PPI
effect. Increasing prepulse intensity resulted in stronger
PPI, and this tendency was evident in all groups.
However, systemic apomorphine (2.0 mg/kg) attenuated
the expression of PPI, and this effect was fully reversed
by the pretreatment of haloperidol at the dose of 1.0 mg/
kg. This contrasts with the lack of any effect by clozapine
pretreatment across all three doses examined, and the
lower dose of haloperidol (0.2 mg/kg), which was not
expected to alleviate the disruption of PPI induced by
apomorphine (see Fig. 1a).
These results were confirmed by the ANOVA of
%PPI, which yielded a significant main effect of
treatment [F(6,60)=4.38, P<0.005], of prepulse levels
[F(4,240)=180.02, P<0.0001], and their interaction
[F(24,240)=2.05, P<0.005]. Pairwise comparisons indi-
cated that PPI was significantly reduced in VEH/APO,
CLZ1.0/APO, CLZ2.0/APO, CLZ3.0/APO, and HAL0.2/
APO groups relative to the VEH/VitC control group [all
P-values <0.05] and the positive control group HAL1.0/
APO. The VEH/VitC and HAL1.0/APO groups did not
differ from each other.
Separate analysis of startle reactivity scores obtained
in pulse-alone trials revealed no significant main effects
of treatment or two-trial blocks. The mean€SEM startle
reactivity (in arbitrary units) for each of the groups is
summarised in Table 1.
Experiment 2 (Basel)
Experiment 2 yielded a similar pattern of results as
experiment 1 in terms of the disruption of PPI by
apomorphine and the lack of an effect by clozapine in
antagonising this effect. The levels of PPI in the VEH–
VitC and in the VEH–APO groups were highly compa-
rable between the two experiments, despite the differ-
ences between the two experiments in terms of reactivity
scores. The latter might be attributed to a difference in the
reference value employed in the two laboratories in the
calibration of the startle detection mechanism. The level
of PPI observed in the three groups receiving clozapine
pretreatment (3–30 mg/kg) did not differ from the VEH–
APO animals. Thus, clozapine in this dose range failed to
antagonise apomorphine-induced PPI disruption (see Fig.
1b).
These conclusions were supported by ANOVA of
%PPI, which revealed a significant main effect of
treatment [F(4,34)=5.65, P<0.001] and of prepulse inten-
sities [F(3,102)=74.33, P<0.0001], but not of their inter-
action [F(12,102)=1.165, P=0.32]. Post hoc Newman–
Keuls analysis confirmed the impression that PPI was
disrupted in all apomorphine-treated groups compared to
the VEH–VitC controls (all P-values <0.05). The mag-
nitude of PPI did not differ among the four apomorphine-
treated groups, regardless of whether they were pretreated
with clozapine.
Fig. 1 a Experiment 1 conducted in Zurich. Average percent
prepulse inhibition (%PPI) across the five different prepulse
intensities measured in mice previously treated with 2.0 mg/kg
apomorphine (APO), vitamin C (VitC), 1–3 mg/kg clozapine (CLZ),
and 0.2–1.0 mg/kg haloperidol (HAL) assigned to one of seven
experimental conditions. Error bars €SEM. n=9–10 per group. b
Experiment 2 conducted in Basel. Average percent prepulse
inhibition (%PPI) across the four different prepulse intensities
measured in mice previously treated with 2.5 mg/kg, SC APO,
VitC, 3–30 mg/kg CLZ. Error bars €SEM. n=6–9 per group.
*Denotes significant difference from VEH–VitC control (P<0.05),
based on Newman–Keuls post hoc comparisons
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Analysis of startle reactivity on startle-alone trials
revealed a significant main effect of treatment [F(4.34)=
7.13, P<0.001]. The mean€SEM startle reactivity for
each of the groups is summarised in Table 1. Post hoc
Newman–Keuls comparisons indicated that reactivity on
startle-alone trials was significantly reduced in all groups
in comparison to the VEH/VitC group (all P-values
<0.05).
Discussion
The present study provides a direct test of whether
apomorphine-induced PPI disruption can be antagonised
by the atypical antipsychotic clozapine, in C57BL/6J
male mice. The clear absence of an effect here was
demonstrated in two independent laboratories using two
different routes of administration, and being conducted in
different phases of the light–dark cycle. Between the two
experiments, clozapine was examined across a dose range
from 1.0 to 30.0 mg/kg. This contrasted with the efficacy
of the typical antipsychotic haloperidol, which completely
restored PPI performance to a normal level at the
appropriate dose (i.e. dose-dependent). These findings
are of significance to behavioural phenotyping in genet-
ically modified mice, especially in the application of the
PPI paradigm as assessment of schizophrenia-related
mutations.
In both experiments, the null effect of clozapine was
clear and was not associated with any tendency of a dose-
dependent effect. Following experiment 1, we attempted
the use of higher doses of clozapine in the Zurich
laboratory using the IP route (6–10 mg/kg), but these were
accompanied by excessive sedation and a massive reduc-
tion in startle reactivity as described earlier by others
(Ouagazzal et al. 2001; Olivier et al. 2001). In experiment
2, the higher doses administered via the PO route still led
to a significant reduction of startle reactivity. Hence,
clozapine was behaviorally effective in the present study,
yet it remained totally ineffective in counteracting the
disruptive effect of apomorphine on PPI.
The present study examined only one mouse strain, and
the generalization of the present findings to other mouse
strains needs to be further explored. The possibility that the
present null effect of clozapine is unique to the C57BL/6J
stain cannot be excluded, given growing evidence that the
expression of PPI and its sensitivity to drug manipulation
can vary significantly across different mouse strains (Varty
et al. 2001; Geyer et al. 2002). Even in the rat, the
effectiveness of clozapine in reversing apomorphine-in-
duced PPI disruption is at least under some circumstances
strain-dependent, although the ability of haloperidol to
antagonise apomorphine-induced PPI disruption is largely
independent of rat strains (see Geyer et al. 2001 for
review). Considering the common use of the C57BL/6J
mouse strain, the present findings should be noted by
researchers in the field of murine behavioral phenotyping.
Nonetheless, the present null findings need to be
considered against (i) the positive effect of clozapine in
the rat, and (ii) the efficacy of clozapine in enhancing PPI
when administered alone in the mouse (e.g. Ouagazzal et
al. 2001).
With respect to the first, there has already been a
recent indication that the pharmacology of PPI might
differ between rats and mice as revealed by the difference
in the dopaminergic modulation of PPI (Ralph-Williams
et al. 2003). These authors suggested that dopamine D1-
family receptors may play a more prominent role in the
modulation of PPI in mice, while the D2-family receptors
appear to be more critically involved in rats. Whether this
particular difference alone could satisfactorily account for
the present ineffectiveness of clozapine remains to be
further evaluated.
As for the second, two recent reports are of particular
relevance. First, Dirks et al. (2003) have shown that
clozapine was not only ineffective in enhancing PPI when
administered alone, but it can even disrupt PPI. This casts
some doubt as to whether clozapine-induced PPI en-
hancement is a robust finding in the mouse. Second, it is
noteworthy that Ralph-Williams et al. (2003) have re-
ported that the selective D1 antagonist, SCH23390, can
reverse apomorphine-induced disruption of PPI, and yet
does not enhance PPI when administered alone. Thus, at
least in mice, PPI enhancement and reversal of apomor-
phine-induced PPI disruption do not always go hand in
hand. With the use of both experimental preparations, PPI
in mice might be useful in dissociating the underlying
neuro-pharmacological mechanisms between the two
phenomena, and potentially in capturing the typical–
atypical dichotomy of antipsychotic drugs.
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